Skip to main navigation Skip to search Skip to main content

Overview of Alopecia Areata

Research output: Contribution to journalReview articlepeer-review

Abstract

Alopecia areata is a complex genetic, immune-mediated disease that targets anagen hair follicles. The disease affects children and adults and is characterized by round or oval patches of hair loss, loss of all scalp hair (alopecia totalis), body hair (alopecia universalis), or ophiasis pattern hair loss. Patients may also present with patchy loss in multiple hair-bearing areas. Commonly associated diseases include asthma, allergic rhinitis, atopic dermatitis, thyroid disease, and automimmune diseases, such as thyroiditis and vitiligo. Nail abnormalities may precede, follow, or occur concurrently with hair loss activity. Alopecia areata has no known age, race, or ethnic preponderance and in contrast to other autoimmune diseases such as thyroiditis or lupus, the hair follicle does not usually sustain permanent injury and maintains its potential to regrow hair. It is estimated that alopecia areata affects between six and seven million individuals in the United States. Genes, the immune and nervous systems have all been implicated in the pathogenesis of alopecia areata. Although many treatments are available, there is still no cure. Bolstered by new scientific and translational opportunities from recently published genome-wide association studies, an ambitious treatment development program has recently been initiated by the National Alopecia Areata Foundation.

Original languageEnglish (US)
Pages (from-to)S13-S15
JournalJournal of Investigative Dermatology Symposium Proceedings
Volume16
Issue number1
DOIs
StatePublished - Dec 2013

Bibliographical note

Funding Information:
Funding for the Summit and publication of this article was provided by the National Alopecia Areata Foundation. MH has received consulting fees from Procter & Gamble, Pantene Institute, and Allergan. MH has also received grant support from Medicis, Allergan, and Novartis Corporation.

Funding Information:
MH has received consulting fees from Procter & Gamble, Pantene Institute, and Allergan. MH has also received grant support from Medicis, Allergan, and Novartis Corporation.

Funding Information:
Funding for the Summit and publication of this article was provided by the National Alopecia Areata Foundation.

Publisher Copyright:
© 2013 The Society for Investigative Dermatology, Inc

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Overview of Alopecia Areata'. Together they form a unique fingerprint.

Cite this